Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Academic and Community Cancer Research United
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05356897CT.gov Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | — | Withdrawn | — | — | — |
NCT05062889CT.gov Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients | — | Suspended | — | — | — |
NCT05130060CT.gov A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03317119CT.gov Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colon Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tipiracil (this asset) | Academic and Community Cancer Research United | P2 | BB · 64 |
| Fluorouracilum | Merck Sharp & Dohme LLC | P3 | BBB |
| Irinotecan | Sun Yat-sen University | P3 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BBB |
| Cetuximab | Merck Sharp & Dohme LLC | P3 | BB |
| Nivolumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Capecitabine | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P3 | BB |
| Pertuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Floxuridine | City of Hope Medical Center | P2 | BB |
+42 more in the Colon Adenocarcinoma cohort
Other indications for Tipiracil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Carcinoma | — | P2 | BBB · 73 |
| Rectal Cancer | — | P2 | BB · 67 |
| Colorectal Cancer | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tipiracil in Colon Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tipiracil-colon-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →